Merck Faces Mounting Regulatory Pressures as IRA Drug Pricing Expands, German Reforms Loom
The pharmaceutical giant's latest 10-Q filing reveals deepening exposure to government price controls across multiple blockbuster drugs while navigating international cost-containment measures.
Regulatory Headwinds Intensify
Merck & Co. disclosed in its second-quarter 10-Q filing that government price-setting programs continue to expand across its product portfolio, with four drugs now subject to the Inflation Reduction Act's Drug Price Negotiation Program. The company reported that Lenvima (lenvatinib) was selected in January 2026 for government price setting effective January 1, 2028, adding to previously announced selections of Januvia, Janumet, and Janumet XR (10-Q filing, 2026-08-07).
The filing indicates that Keytruda, Merck's flagship oncology drug, is expected to be selected in 2027 for government price setting effective January 1, 2029. Combined global sales of Keytruda and Keytruda Qlex grew 5% and 8% in the second quarter and first six months of 2026, respectively, driven by higher net pricing and increased demand across earlier-stage indications including triple-negative breast cancer and bladder cancer (10-Q filing, 2026-08-07).
German Healthcare Reforms Add Pressure
In July 2026, the German parliament approved the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG), introducing "significant cost-containment measures" with most provisions taking effect January 1, 2027. Merck stated it "is currently evaluating the implications" but acknowledged "the provisions of this law will exert significant downward pressure on sales in Germany" (10-Q filing, 2026-08-07).
The company's performance in the first six months of 2026 was "negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs," with the filing noting that international markets have seen "government-mandated pricing actions" reducing prices of both generic and patented drugs (10-Q filing, 2026-08-07).
Most-Favored-Nation Agreement Details
Merck's December 2025 three-year agreement with the U.S. government includes several commitments: direct-to-patient programs for Januvia, Janumet, and Janumet XR at "affordable prices" for eligible patients, with plans to expand to include Lipfendra (enlicitide). The company agreed to offer existing medicines at discounted prices to Medicaid and signed a June 2026 agreement to participate in the GENEROUS Model, aligning certain medication prices with select countries (10-Q filing, 2026-08-07).
Under the agreement, products launched during the MFN Agreement term will be "subject to most-favored-nation pricing in reference to prices for such products in a specified group of countries." The company also agreed to "repatriate and share with the Federal government a portion of foreign revenue" resulting from trade policy efforts (10-Q filing, 2026-08-07).
Strategic Acquisitions and Revenue Performance
Despite regulatory pressures, Merck reported worldwide sales of $16.6 billion and $32.9 billion in the second quarter and first six months of 2026, representing 5% increases compared with 2025. The company completed two significant acquisitions: a $9.2 billion purchase of Cidara Therapeutics in January 2026 for influenza candidate MK-1406, resulting in a $9.0 billion charge to R&D expenses, and a $650 million acquisition of TARGAN in July 2026 to expand animal health capabilities in poultry operations (10-Q filing, 2026-08-07).
MarginX data shows a special call scheduled for October 26, 2026, and recent insider activity including a 15,000-share sale by Chirfi Guindo.
This article was generated by MarginX from the 10-Q filing on 2026-08-07. It is not investment advice.